In recent analyst activity, Axogen (AXGN, Financial) has been the subject of a price target adjustment by Canaccord Genuity. Analyst Caitlin Cronin from Canaccord Genuity has made a strategic move by lowering the price target for Axogen from $26.00 to $24.00. This adjustment reflects a change of -7.69% from the previous target.
Despite this revision, Canaccord Genuity maintains a 'Buy' rating for Axogen (AXGN, Financial). The 'Buy' rating remains unchanged, indicating continued analyst confidence in the stock's potential, despite the lowered price target.
This update took effect as of May 13, 2025, and it underscores the nuanced shifts in the valuation assessments of Axogen (AXGN, Financial) by industry analysts. Investors and stakeholders of Axogen are advised to note these developments as part of their ongoing evaluation of the company's market performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Axogen Inc (AXGN, Financial) is $24.38 with a high estimate of $30.00 and a low estimate of $21.00. The average target implies an upside of 117.25% from the current price of $11.22. More detailed estimate data can be found on the Axogen Inc (AXGN) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Axogen Inc's (AXGN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Axogen Inc (AXGN, Financial) in one year is $13.88, suggesting a upside of 23.71% from the current price of $11.22. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Axogen Inc (AXGN) Summary page.
